Supplementary Figures S1-S9 from Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia

Phosphotyrosine sites identified by immunoaffinity profiling in ALL PDXs (S1); Comparison of phosphotyrosine enrichment from fresh and frozen PDX (S2); Optimization of quantitative phosphotyrosine profiling of pediatric ALL PDXs (S3); Number of identified Class I phosphosites in each of the PDXs (S4); Unsupervised hierarchical clustering of Class I phosphosites in ALL PDXs segregated based on molecularly-defined subgroups (S5); Comparison of ETP-ALL, Ph-like-ALL, BCP-ALL and T-ALL PDXs by gene expression profiling (S6); Comparison of phosphorylation levels of pTyr sites with gene expression profiling (S7); In vitro sensitivity of ALL PDXs to Sunitinib (S8); Venn diagram showing the number of Light PDX phosphopeptides and Heavy SILAC labelled phosphopeptides identified in each of the 16 PDXs (S9).